Click here to close now.

SYS-CON MEDIA Authors: Rex Morrow, Datical, Liz McMillan, John Wetherill, Ruxit Blog, Hovhannes Avoyan

News Feed Item

Global Diabetes Devices Market And Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share & Forecast 2011 - 2018

NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Diabetes Devices Market And Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share & Forecast 2011 - 2018

http://www.reportlinker.com/p01081284/Global-Diabetes-Devices-Market-And...

Description

This report is an effort to identify factors, which will be the driving force behind the diabetes devices and drugs market and sub-markets in the next few years. The report provides extensive analysis of the industry, current market trends, industry drivers and challenges for better understanding of the market structure. The report has segregated the diabetes devices and drugs industry in terms of product and geography. We have used a combination of primary and secondary research to arrive at the market estimates, market shares and trends. We have adopted bottom up model to derive market size of the global diabetes devices and drugs market and further validated numbers with the key market participants and C-level executives.

This report highlights the industry with the following points:

Definition, estimates & forecast of diabetes devices and drugsproduct market from 2010 to 2018Analysis of product segments for diabetes devices and drugs product market with historical data and forecastTrends and forecast for four geographic markets, namely the U.S., Europe, Asia-Pacific, Middle East and Africa and Latin America based on segments of diabetes devices and drugs product marketProfiles of major market participants for better understanding of their contributions

This research is specially designed to estimate and analyze the demand and performance of diabetes devices and drugs products in a global scenario. The research provides in-depth analysis of diabetes devices and drugs product manufacturers, product sales, trend analysis by segments and demand by geography. The report covers all the major product segments of the global diabetes devices and drugs market, and provide historical data and statistically refined forecast for the segments covered. The study presents a comprehensive assessment of the stakeholder strategies and winning imperatives for them by segmenting the global diabetes devices and drugs market as below:

Diagnosis and Monitoring Devices Market

Blood Glucose Monitoring Devices

Lancets

Blood Sampling Devices

Blood Glucose Meters

New Development in Glucose Testing

Other Testing Devices

Hemoglobin A1c

Hemoglobin A1c Meters

Hemoglobin A1c Kits

Others

Software Programs for Diabetes Monitoring

Web Software

Commercial Software

Artificial Pancreas

Therapeutics Devices and Drugs Market

Insulin

By Action

Short Acting

Pre-Mixes

Long Acting

By Type

Human Insulin

Modern Insulin

Animal Insulin

By Purchase Type

Dosage

Bulk

Insulin Delivery

Syringes

Pens

Injectors

Inhaled Insulin

Insulin Pumps

Oral Hypoglycemic Agents

KATP Blocker

Biguanides

Alpha-Glucosidase Inhibitor

Thiazolinediones/ Glitazones

IncretinMimetics/ GLP-1 Analogs

DPP-4 Inhibitors

Amylin Mimetic

SGLT2 Inhibitors

Other

Cell Therapies

In addition the report provides a cross-sectional analysis of all the above segments with respect to following geographical markets:

North AmericaEuropeAsia-PacificMiddle East and AfricaLatin America

The in-depth research and high level analysis will allow diabetes devices and drugs product manufacturers, lawmakers, large retailers, medical companies and research and development agencies to make informed decisions about diabetes devices and drugs products manufacturing, designing marketing, growth strategies and gaining competitive advantage.?

TABLE OF CONTENTS

CHAPTER 1 PREFACE

1.1 REPORT DESCRIPTION

1.2 SCOPE OF THE REPORT

1.3 METHODOLOGY

1.4 ASSUMPTIONS

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 GLOBAL DIABETES MARKET ANALYSIS

3.1 DIABETES: AGE-GROUP ANALYSIS

3.2 MARKET OVERVIEW

3.3 KEY MARKET TRENDS

3.4 GLOBAL DIABETES MARKET SIZE AND FORECAST, 2010 – 2018

3.4.1 TYPE I DIABETES MARKET SIZE AND FORECAST

3.4.2 TYPE II DIABETES MARKET SIZE AND FORECAST

3.4.3 DIABETES DEVICES MARKET SIZE AND FORECAST

3.4.4 DIABETES DRUGS MARKET SIZE AND FORECAST

3.5 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)

3.6 MARKET DYNAMICS

3.6.1 DRIVERS

3.6.1.1 Growing Diabetic Population around the Globe

3.6.1.2 Changing Lifestyle and Obesity as a Leading Cause of Diabetes

3.6.1.3 Launch of New Generation Innovative Drugs Likely to Attract Consumers

3.6.2 RESTRAINTS

3.6.2.1 Lack of Awareness about Diabetes Diagnostics and Treatment

3.6.2.2 Adverse side-effects of drugs and the resulting litigation issues

3.6.3 OPPORTUNITIES

3.6.3.1 Increasing Awareness may Unleash the Untapped Market

3.7 IMPACT OF REGULATIONS ON TYPE II DIABETES MARKET GROWTH

3.7.1 RISE IN THE NUMBER OF BACKLOG OF DRUGS UNDER FDA REVIEW AND THE SHIFTING TIMELINES FOR THE SAME IN THE UNITEDSTATES

3.7.2 REGULATORS' LAY MORE EMPHASIS ON ADEQUATE SAFETY DATA INSTEAD OF RELYING ONLY ON EFFICACY DATA FOR DRUG APPROVAL AND NEW DIRECTIVES FOR PATIENT SCREENING IN THE UNITED STATES

3.7.3 PROMOTION OF LOW-COST GENERICS TO LIMIT HEALTHCARE COSTS, HEALTHCARE INSURERS' AND REGULATORS'

3.7.4 IN EMERGING MARKETS SUCH AS ASIA, PRICING CONTROLS ARE LIKELY TO BE PUT IN PLACE

3.8 FACTORS AFFECTING GLOBAL DIABETES DEVICES AND DRUGS MARKET

3.8.1 RISING INCIDENCE OF DIABETES IN KEY MARKETS SUCH AS U.S., U.K. AND GERMANY

3.8.2 RISING EDUCATION IS EXPECTED TO DECREASE DIABETES PREVALENCE BY 1.2%

3.8.3 PEOPLE WITH A DIABETES PARENT LEADS TO AN INCREASE OF 1.4%

3.8.4 SOCIAL FACTORS AFFECTING DIABETE

3.9 PORTERS FIVE FORECES ANALYSIS OF DIABETES DEVICES AND DRUGS MARKET

3.9.1 BUYERS' POWER

3.9.2 SUPPLIERS' POWER

3.9.3 EXISTING RIVALRY

3.9.4 THREAT OF NEW ENTRANTS

3.9.5 THREAT OF SUBSTITUTE

3.10 GLOBAL DIABETES DRUGS AND DEVICES REGULATORY SCENARIO

CHAPTER 4 GLOBAL DIABETES DEVICES AND DRUGS MARKET4.1 GLOBAL DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE2010 – 20184.1.1 BLOOD GLUCOSE MONITORING DEVICES, MARKET SIZE AND FORECAST4.1.1.1 Lancets4.1.1.2 Blood Sampling Devices4.1.1.3 Blood Glucose Monitors4.1.1.3.1 Drivers4.1.1.3.1.1 Increasing awareness and simpler devices4.1.1.3.1.2 Increase in disposable income4.1.1.3.1.3 Declining prices4.1.1.3.1.4 Improving compatibility4.1.1.3.2 Restraints4.1.1.3.2.1 Increase in competition leading to low prices4.1.1.3.2.2 Private label brands4.1.1.3.2.3 Awareness among patients is still a challenge4.1.1.3.3 Key trends4.1.1.4 New Development in Glucose Testing4.1.2 OTHER TESTING DEVICES MARKET SIZE AND FORECAST4.1.2.1 Hemoglobin A1c4.1.2.1.1 Hemoglobin A1c Meters4.1.2.1.2 Hemoglobin A1c Kits4.1.2.2 Others4.1.3 SOFTWARE PROGRAMS FOR DIABETES MONITORING, MARKET SIZE AND FORECAST4.1.3.1 Web Software Programs for Diabetes Monitoring4.1.3.2 Commercial Software4.1.4 ARTIFICIAL PANCREAS, MARKET SIZE AND FORECAST4.2 GLOBAL DIABETES THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2011 – 20184.2.1 DRIVERS4.2.1.1 Improved Delivery Devices4.2.1.2 Increased Risk with Oral Anti-Diabetes Drugs4.2.1.3 Technological Advancement4.2.2 RESTRAINTS4.2.2.1 Associated Pain4.2.2.2 Market boom for New Generation diabetic drugs4.2.2.3 Cost Issues4.2.3 OPPORTUNITIES4.2.3.1 Novel insulin delivery method4.2.4 GLOBAL ORAL DIABETES DRUG MARKET4.2.4.1 Popular Anti-Diabetic Drugs World wide4.2.4.2 Drivers4.2.4.2.1 Novel drugs driving the market growth4.2.4.2.2 Patent expiry of popular drugs4.2.4.2.3 Painless Option4.2.5 RESTRAINTS4.2.5.1 Associated high risks4.2.5.2 Improving options of insulin delivery devices4.2.5.3 Trend of diabetic diet4.2.6 OPPORTUNITIES4.2.6.1 Diabetes Vaccines4.2.6.2 Leveraging the patent expiry of popular drugs4.2.7 INSULIN, MAKET SIZE AND FORECAST 4.2.7.1 Market Size and Forecast4.2.7.2 Global Insulin Market Share of Major Players, 2011 4.2.7 2.1 Global Human Insulin Market Share of Major Players, 2011 4.2.7 2.2 Global Modern Insulin Market Share of Major Players, 20114.2.7.3 Insulin Market Size and Forecast, By Action4.2.7.3.1 Short Acting4.2.7.3.2 Pre-Mixes4.2.7.3.3 Long Acting4.2.7.4 Insulin Market Size and Forecast, by Type4.2.7.4.1 Human Insulin4.2.7.4.2 Modern Insulin4.2.7.4.3 Animal Insulin4.2.7.5 Insulin Market Size and Forecast, by Purchase Type4.2.7.5.1 Dosage4.2.7.5.2 Bulk4.2.8 INSULIN, DELIVERY MAKET SIZE AND FORECAST4.2.8.1 Insulin Syringes Maket Size and Forecast 4.2.8.2 Insulin Pens Maket Size and Forecast4.2.8.3 Insulin Injectors Maket Size and Forecast 4.2.8.4 Inhaled Insulin Maket Size and Forecast 4.2.8.5 Insulin Pumps Maket Size and Forecast 4.2.8.5.1 Drivers4.2.8.5.1.1 Growing Diabetic Population4.2.8.5.1.2 Advancement in Technology4.2.9 ORAL HYPOGLYCEMIC AGENTS, MAKET SIZE AND FORECAST4.2.9.1 KATP Blocker Maket Size and Forecast4.2.9.2 Biguanides Maket Size and Forecast 4.2.9.3 Alpha-Glucosidase Inhibitor Maket Size and Forecast 4.2.9.4 Thiazolinediones/ Glitazones Maket Size and Forecast 4.2.9.5 Incretin Mimetics/ GLP-1 Analogs Maket Size and Forecast 4.2.9.6 DPP-4 InhibitorMaket Size and Forecast 4.2.9.7 Amylin Mimetic Maket Size and Forecast 4.2.9.8 SGLT2 Inhibitors Maket Size and Forecast 4.2.9.9 Other Oral Hypoglycemic Agents Maket Size and Forecast 4.2.10 CELL THERAPIES MAKET SIZE AND FORECAST

CHAPTER 5 GEOGRAPHY ANALYSIS

5.1 GLOBAL OVERVIEW

5.2 EUROPE DIABETES DEVICES AND DRUGS MARKET

5.2.1 INNOVATION DRIVING THE EUROPEAN MARKET

5.2.1.1 Undiagnosed patients high in European countries

5.2.1.2 Increasing R&D costs

5.2.2 RESTRAINTS

5.2.2.1 Case1

5.2.2.2 Case 2

5.2.2.3 Case 3

5.2.3 OPPORTUNITIES

5.2.3.1 Undiagnosed Diabetic Patient Population in Europe

5.2.4 EUROPE DIABETES MARKET SHARE OF MAJOR PLAYERS

5.2.5 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.2.5.1 Blood glucose monitoring devices, maket size and forecast

5.2.5.2 Other dibetes testing devices, maket size and forecast

5.2.5.3 Software programs for diabetes monitoring, maket size and forecast

5.2.5.4 Artificial pancreas, maket size and forecast

5.2.6 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.2.6.1 Insulin, maket size and forecast

5.2.6.2 Insulin delivery, maket size and forecast

5.2.6.3 Oral hypoglycemic agents, maket size and forecast

5.2.6.4 Cell therapies, maket size and forecast

5.3 ASIA PACIFIC DIABETES DEVICES AND DRUGS MARKET

5.3.1 CHINA

5.3.2 INDIA

5.3.3 SOUTH KOREA

5.3.4 TAIWAN

5.3.5 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.3.5.1 Blood glucose monitoring devices, maket size and forecast

5.3.5.2 Other dibetes testing devices, maket size and forecast

5.3.5.3 Software programs for diabetes monitoring, maket size and forecast

5.3.5.4 Artificial pancreas, maket size and forecast

5.3.6 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.3.6.1 Insulin, maket size and forecast

5.3.6.2 Insulin delivery, maket size and forecast

5.3.6.3 Oral hypoglycemic agents, maket size and forecast

5.3.6.4 Cell therapies, maket size and forecast

5.4 NORTH AMERICA DIABETES DEVICES AND DRUGS MARKET

5.4.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.4.1.1 Blood glucose monitoring devices, maket size and forecast

5.4.1.2 Other dibetes testing devices, maket size and forecast

5.4.1.3 Software programs for diabetes monitoring, maket size and forecast

5.4.1.4 Artificial pancreas, maket size and forecast

5.4.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.4.2.1 Insulin, maket size and forecast

5.4.2.2 Insulin delivery, maket size and forecast

5.4.2.3 Oral hypoglycemic agents, maket size and forecast

5.4.2.4 Cell therapies, maket size and forecast

5.5 MIDDLE EAST AND AFRICA DIABETES DEVICES AND DRUGS MARKET

5.5.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.5.1.1 Blood glucose monitoring devices, maket size and forecast

5.5.1.2 Other dibetes testing devices, maket size and forecast

5.5.1.3 Software programs for diabetes monitoring, maket size and forecast

5.5.1.4 Artificial pancreas, maket size and forecast

5.5.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.5.2.1 Insulin, maket size and forecast

5.5.2.2 Insulin delivery, maket size and forecast

5.5.2.3 Oral hypoglycemic agents, maket size and forecast

5.5.2.4 Cell therapies, maket size and forecast

5.6 LATIN AMERICDIABETES DEVICES AND DRUGS MARKET

5.6.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.6.1.1 Blood glucose monitoring devices, maket size and forecast

5.6.1.2 Other dibetes testing devices, maket size and forecast

5.6.1.3 Software programs for diabetes monitoring, maket size and forecast

5.6.1.4 Artificial pancreas, maket size and forecast

5.6.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.6.2.1 Insulin, maket size and forecast

5.6.2.2 Insulin delivery, maket size and forecast

5.6.2.3 Oral hypoglycemic agents, maket size and forecast

5.6.2.4 Cell therapies, maket size and forecast

CHAPTER 6 COMPETITIVE LANDSCAPE6.1 SUMMARY6.2 MARKET SHARE OF MAJOR PLAYERS: GLOBAL DIABETES MARKET6.3 GLOBAL DIABETES DEVICES MARKET SHARE OF MAJOR PLAYERS6.4 GLOBAL DIABETES THERAPEUTIC MARKET SHARE OF MAJOR PLAYERS6.4.1 INSULIN DELIVERY MARKET PLAYERS6.4.2 GLOBAL DIABETES DRUGS MARKET SHARES OF MAJOR PLAYERS6.5 CLINICAL TRIALS6.6 RECENT DEVELOPMENTS6.7 COMPETITIVE STRATEGY BY KEY PLAYERS

CHAPTER 7 COMPANY PROFILE

7.1 ABBOTT LABORATORIES

7.1.1 COMPANY OVERVIEW

7.1.2 REVENUE SHARE

7.1.3 RECENT DEALS

7.2 BRISTOL-MYERS SQUIBB (BMS)

7.2.1 COMPANY OVERVIEW

7.2.2 REVENUE SHARE

7.2.3 RECENT DEALS

7.3 DEXCOM

7.3.1 COMPANY OVERVIEW

7.3.2 REVENUE SHARE

7.3.3 RECENT DEALS

7.4 ELI LILLY

7.4.1 COMPANY OVERVIEW

7.4.2 REVENUE SHARE

7.4.3 RECENT DEALS

7.5 GLAXOSMITHKLINE

7.5.1 COMPANY OVERVIEW

7.5.2 REVENUE SHARE

7.5.3 RECENT DEALS

7.6 GLENMARK PHARMACEUTICALS

7.6.1 COMPANY OVERVIEW

7.6.2 REVENUE SHARE

7.6.3 RECENT DEALS

7.7 JOHNSON&JOHNSON

7.7.1 COMPANY OVERVIEW

7.7.2 REVENUE SHARE

7.7.3 RECENT DEALS

7.8 LUPIN

7.8.1 COMPANY OVERVIEW

7.8.2 REVENUE SHARE

7.8.3 RECENT DEALS

7.9 ROCHE

7.9.1 COMPANY OVERVIEW

7.9.2 REVENUE SHARE

7.9.3 RECENT DEALS

7.10 SANOFI

7.10.1 COMPANY OVERVIEW

7.10.2 REVENUE SHARE

7.10.3 RECENT DEALS

LIST OF FIGURES

FIG. 1 GLOBAL PREVALENCE OF DIABETES AMONG VARIOUS AGE GROUPS

FIG. 2 GLOBAL DIABETES PREVELANCE, BY COUNTRY 2011

FIG. 3 DRUGS VS. DEVICES MARKET SHARE

FIG. 1 GLOBAL DIABETES DEVICES AND DRUGS MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)

FIG. 2 TYPE-I DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 3 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 4 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 5 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 6 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)

FIG. 7 COUNTRY WISE DIABETES PATIENTS FORECAST, BY 2030 (MILLION)

FIG. 8 NUMBER OF DIABETES DRUGS IN DEVELOPMENT BY PHASE UNITED STATES, 2012

FIG. 9 NUMBER OF PEOPLE LEFT UNDIAGNOSED IN U.S., 2011 (MILLIONS)

FIG. 10 GLOBAL DIABETES DIAGNOSIS AND MONETORING MARKET SIZE AND FORECAST, BY CATEGORY 2010 - 2018 (USD MILLION)

FIG. 11 BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 12 LANCETS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 13 BLOOD SAMPLING BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 14 MARKET SHARES (U.S. VS OTHERS)

FIG. 15 MARKET SHARE OF SMBG TESTING IN THE INVITRO- DIAGNOSTIC MARKET GLOBALLY

FIG. 16 BLOOD GLUCOSE METERS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 17 NEW DEVELOPMENTS IN GLUCOSE TESTING BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 18 OTHER TESTING DEVICES BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 19 HEMOGLOBIN A1C BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 20 HEMOGLOBIN A1C METERS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 21 HEMOGLOBIN A1C KITS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 22 OTHER A1C BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 23 SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 24 WEB SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 25 COMMERCIAL SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 26 ARTIFICIAL PANCREAS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 27 MARKET SHARE

FIG. 28 GLOBAL DIABETES THERAPEUTICS DEVICES AND DRUGS MARKETMARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 29 GLOBAL INSULINMARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 30 GLOBAL INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011

FIG. 31 GLOBAL MODERN INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011

FIG. 32 GLOBAL HUMAN INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011

FIG. 33 SHORT ACTING INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)

FIG. 34 PRE-MIXES INSULIN MARKET SIZE AND FORECAST, BY ACTION 2010 - 2018 (USD MILLION)

FIG. 35 LONG ACTING INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)

FIG. 36 HUMAN INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)

FIG. 37 HUMAN INSULIN MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 38 HUMAN INSULIN MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 39 INSULIN MARKET DOSAGE SIZE AND FORECAST, BY PURCHASE TYPE 2010 - 2018 (USD MILLION)

FIG. 40 INSULIN MARKET BULK SIZE AND FORECAST, BY PURCHASE TYPE 2010 - 2018 (USD MILLION)

FIG. 41 GLOBAL INSULIN DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 42 INSULIN SYRINGES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 43 INSULIN PENS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 44 INSULIN INJECTORS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 45 INHALED INSULIN DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 46 INSULIN PUMPS MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 47 KEY PARTICIPANTS: MARKET SHARES (2011)

FIG. 48 ORAL HYPOGLYCEMIC AGENTS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 49 KATP BLOCKER MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 50 BIGUANIDES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 51 ALPHA-GLUCOSIDASE INHIBITOR DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 52 THIAZOLINEDIONES/ GLITAZONES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 53 INCRETIN MIMETICS/ GLP-1 ANALOGS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 54 DPP-4 INHIBITORS MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 55 AMYLIN MIMETIC DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 56 SGLT2 INHIBITORS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 57 OTHER ORAL HYPOGLYCEMIC AGENTS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 58 CELL THERAPIES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 59 DIABETES PREVALENCE IN EUROPE

FIG. 60 POPULATION DISTRIBUTION WITH DIABETES (INITIATING DPP-IV, TZD, GLP-1 OR INSULIN)

FIG. 61 UNDIAGNOSED DIABETIC POPULATION

FIG. 62 EUROPEAN DIABETES DRUGS MARKET SHARE (2012)

FIG. 63 DISTRIBUTION OF DIABETES DRUG MARKET IN EUROPE

FIG. 64 DIABETES PREVALENCE IN ASIAN COUNTRIES

FIG. 65 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)

FIG. 66 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)

FIG. 67 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)

FIG. 68 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)

FIG. 69 MARKET SHARE OF ABBOTT LABORATORIES

FIG. 70 REVENUE SHARES OF ABBOTT LABORATORIES

FIG. 71 REVENUE TRENDS OF DEXCOM

FIG. 72 REVENUE TRENDS OF ELI LILLY

FIG. 73 REVENUE CONTRIBUTIONOF ELI LILLY

FIG. 74 REVENUE TREND OF GLAXOSMITH

FIG. 75 REVENUE TREND OF GLAXOSMITH

FIG. 76 REVENUE TREND OF GLENMARK PHARMACEUTICALS

FIG. 77 REVENUECONTRIBUTION OF JOHNSON&JOHNSON

FIG. 78 REVENUE TREND OF JOHNSON&JOHNSON

FIG. 79 REVENUE TREND OF LUPIN

FIG. 80 REVENUE TREND OF ROCHE

FIG. 81 REVENUE CONTRIBUTION OF SANOFI

FIG. 82 REVENUE TREND OF SANOFI

LIST OF TABLES

TABLE 1 OBESITY RATE IN THE U.S., BY STATE 2011 (%)

TABLE 2 CLINICAL TRIALS: US (ORAL ANTI-DIABETES DRUGS)

TABLE 3 CLINICAL TRIALS: CHINA (ORAL ANTI-DIABETES DRUGS)

TABLE 4 CLINICAL TRIALS: JAPAN (ORAL ANTI-DIABETES DRUGS)

TABLE 5 CLINICAL TRIALS: INDIA (ORAL ANTI-DIABETES DRUGS)

TABLE 6 CLINICAL TRIALS: UNITED KINGDOM (ORAL ANTI-DIABETIC DRUGS)

TABLE 7 CLINICAL TRIALS: GERMANY (ORAL ANTI-DIABETIC DRUGS)

TABLE 8 CLINICAL TRIALS: FRANCE (ORAL ANTI-DIABETIC DRUGS)

TABLE 9 CLINICAL TRIALS: US (ANTI-DIABETIC INJECTABLES)

TABLE 10 CLINICAL TRIALS: JAPAN (ANTI-DIABETIC INJECTABLES)

TABLE 11 CLINICAL TRIALS: CHINA (ANTI-DIABETIC INJECTABLES)

TABLE 12 CLINICAL TRIALS: INDIA (ANTI-DIABETIC INJECTABLES)

TABLE 13 CLINICAL TRIALS: GERMANY (ANTI-DIABETIC INJECTABLES)

TABLE 14 CLINICAL TRIALS: UNITED KINGDOM (ANTI-DIABETIC INJECTABLES)

TABLE 15 CLINICAL TRIALS: GERMANY (ANTI-DIABETIC INJECTABLES)

TABLE 16 GLOBAL DIABETES DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY GEOGRAPHY 2012 – 2018

TABLE 17 EUROPE DIABETES MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)

TABLE 18 EUROPE DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE2012 – 2018 (USD MILLION)

TABLE 19 EUROPE DIABETES THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)

TABLE 20 ASIA PACIFIC DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 21 ASIA PACIFIC DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPEBY TYPE, 2012 – 2018 (USD MILLION)

TABLE 22 ASIA PACIFIC THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 23 NORTH AMERICA DIABETES MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)

TABLE 24 NORTH AMERICA DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPEBY TYPE, 2012 – 2018 (USD MILLION)

TABLE 25 NORTH AMERICA THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 29 LATIN AMERICA DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 30 LATIN AMERICADIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 31 LATIN AMERICATHERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 32 CLINICAL TRIALS: UNITED STATES (INSULIN PUMPS)

TABLE 33 CLINICAL TRIALS: UNITED KINGDOM (INSULIN PUMPS)

TABLE 34 CLINICAL TRIALS: FRANCE (INSULIN PUMPS)

TABLE 35 CLINICAL TRIALS: GERMANY (INSULIN PUMPS)

TABLE 36 CLINICAL TRIALS: CHINA (INSULIN PUMPS)

TABLE 37 CLINICAL TRIALS: UNITED STATES (GLUCOSE MONITORS)

TABLE 38 CLINICAL TRIALS: UNITED KINGDOM (GLUCOSE MONITORS)

TABLE 39 CLINICAL TRIALS: FRANCE (GLUCOSE MONITORS)

TABLE 40 CLINICAL TRIALS: CHINA (GLUCOSE MONITORS)

To order this report:Drug_and_Medication Industry: Global Diabetes Devices Market And Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share & Forecast 2011 - 2018

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The multi-trillion economic opportunity around the "Internet of Things" (IoT) is emerging as the hottest topic for investors in 2015. As we connect the physical world with information technology, data from actions, processes and the environment can increase sales, improve efficiencies, automate daily activities and minimize risk. In his session at @ThingsExpo, Ed Maguire, Senior Analyst at CLSA Americas, will describe what is new and different about IoT, explore financial, technological and re...
"At Harbinger we do products as well as services. Our services are with helping companies move their products to the cloud operating systems. Some of the challenges we have seen as far as cloud adoption goes are in the cloud security space," noted Shrikant Pattathil, Executive Vice President at Harbinger Systems, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
"At our booth we are showing how to provide trust in the Internet of Things. Trust is where everything starts to become secure and trustworthy. Now with the scaling of the Internet of Things it becomes an interesting question – I've heard numbers from 200 billion devices next year up to a trillion in the next 10 to 15 years," explained Johannes Lintzen, Vice President of Sales at Utimaco, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in San...
Aria Systems, which helps enterprises grow recurring revenue, today announced that its co-founder and inventor of cloud billing Brendan O'Brien, will be a featured speaker at the Cloud Expo, June 9-11 at The Javits Center in New York. Aria also will be demonstrating its Active Monetization platform in Booth #424 on the Expo Floor. O'Brien will lead the following sessions: June 9 - 11:00 am - 11:35 am, Room 1A16 with participants from Constant Contact, MGI Research and ATG Enabling Complex ...
"For the past 4 years we have been working mainly to export. For the last 3 or 4 years the main market was Russia. In the past year we have been working to expand our footprint in Europe and the United States," explained Andris Gailitis, CEO of DEAC, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
"Our premise is Docker is not enough. That's not a bad thing - we actually love Docker. At ActiveState all our products are based on open source technology and Docker is an up-and-coming piece of open source technology," explained Bart Copeland, President & CEO of ActiveState Software, in this SYS-CON.tv interview at DevOps Summit at Cloud Expo®, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today DevOps.com will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. Launched in 2014, DevOps.com has quickly established itself as an indispensable resource for DevOps education and community building. DevOps.com make it their mission to cover all aspects of DevOps – philosophy, tools, business impact, best practices and more.
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
The web app is Agile. The REST API is Agile. The testing and planning are Agile. But alas, Data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes which force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software orga...
IndependenceIT has been selected by nGenx to power Windows-based DaaS and application delivery on Google Compute Engine to support the delivery of GoldMine Cloud software. For independent software vendors (ISVs) like GoldMine, this expands the theater of operations to increase revenue opportunities while reducing software management and maintenance liabilities. IndependenceIT was selected by application and desktop pioneer, nGenx, to deliver its “Bring Your Own Cloud” strategy to GoldMine and o...
Growth hacking is common for startups to make unheard-of progress in building their business. Career Hacks can help Geek Girls and those who support them (yes, that's you too, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is there a bias against women in the tech / developer communities? Why are women 50% of the workforce, but hold only 24% of the STEM or IT positions? Some beginnings of what to do about it!
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. 8th International Big Data Expo, co-located with 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. As advanced data storage, access and analytics technologies aimed at handling high-volume and/or fast moving data all move center stage, aided by the cloud computing bo...
SYS-CON Events announced today that the "First Containers & Microservices Conference" will take place June 9-11, 2015, at the Javits Center in New York City. The “Second Containers & Microservices Conference” will take place November 3-5, 2015, at Santa Clara Convention Center, Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
"We are the top stocking distributor for HP renew products in North America. We can only sell to U.S. authorized partners and resellers for HP," explained Miguel Diazdelcastillo Jr., Sales Executive at Creative Business Solutions, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
"Ulunsoft is a start-up that focuses on how enterprises build cloud-based IT infrastructure for business," explained Haibo Zhu, President of Ulunsoft Corp, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.